Revised credit deal gives Boston more breathing space:
This article was originally published in Clinica
Boston Scientific has renegotiated the terms of a $2bn revolving credit line and $5bn loan agreement, which will provide the Natick, Massachusetts company with "significant financial flexibility" as it pursues its strategy to boost shareholder value. It added that it has paid off $1bn of the loan, leaving it with nearly $1bn cash on hand and full access to $2bn of available revolving credit. Interest rate margins and fee rates for the amended credit facility remain unchanged. Boston's weakening product sales, amid sluggish market conditions, and heavy debt related to its Guidant acquisition have prompted the company to undertake a number of restructuring initiatives to help its finances. These initiatives include divesting non-core assets and cutting expenses and the size of its workforce.
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.